Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia

Justin C. Boucher, PhD, Bin Yu, Gongbo Li, PhD MBBS, Bishwas Shrestha, PhD, Jeffrey E. Lancet, MD, David A. Sallman, MD, Ana Marie Landin, Adam William Mailloux, PhD, Claudio Anasetti, MD, Linda L. Kelley, PhD, Marco L. Davila, MD PhD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136174

Published: 2020

Journal Articles

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

David A. Sallman, MD, Hany Elmariah, MD MS, Kendra L. Sweet, MD MS, Chetasi Talati, MD, Asmita Mishra, MD, Linda L. Kelley, PhD, Amy Lankford, PhD, Tim Chan, PhD, Rutul R Shah, Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Helen Sabzevari, PhD, Marco L. Davila, MD PhD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-139417

Published: 2020

Journal Articles

Ex Vivo Expansion of CD34+ Cells From Cord Blood, Bone Marrow, and Mobilized Peripheral Blood Using NANEX Nanofiber Scaffold

Stephen L Fischer, PhD, Jacqueline M Fonseca, Yukang Zhao, Linda L. Kelley, PhD, Ramasamy Sakthivel, PhD

Blood (2011) 118 (21): 4816.

https://doi.org/10.1182/blood.V118.21.4816.4816

Published: 2011

Journal Articles

Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27 Kip1 and inactivation of cdk2 kinase

Fen F. Hsieh, Lou Ann Barnett, Wayne F. Green, Karen Freedman, Igor Matushansky, Arthur I. Skoultchi, Linda L. Kelley

Blood (2000) 96 (8): 2746–2754.

https://doi.org/10.1182/blood.V96.8.2746

Published: 2000

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

Ex Vivo Expansion of CD34+ Cells From Cord Blood, Bone Marrow, and Mobilized Peripheral Blood Using NANEX Nanofiber Scaffold

Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27 Kip1 and inactivation of cdk2 kinase

Email alerts

ASH Publications

American Society of Hematology

Update search

Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

Ex Vivo Expansion of CD34+ Cells From Cord Blood, Bone Marrow, and Mobilized Peripheral Blood Using NANEX Nanofiber Scaffold

Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27 Kip1 and inactivation of cdk2 kinase

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only